中金辐照股份有限公司独立董事关于第三届 董事会第二十九次会议相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司独立董事规则》《深圳证券交易所上市公司 自律监管指引第 2 号-创业板上市公司规范运作》等有关法 律、法规、规范性文件及《公司章程》等相关文件的规定， 公司独立董事就公司第三届董事会第二十九次会议相关事 项发表独立意见如下： 一、关于控股股东及其他关联方占用公司资金和公司对 外担保情况的专项说明和独立意见 四、关于董事会换届选举暨提名第四届董事会非独立董 事候选人的独立意见 经认真审核，独立董事一致认为：公司第三届董事会任 期届满，本次换届选举符合《公司法》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》 等法律法规以及《公司章程》的有关规定，非独立董事候选 人的提名及审议程序合法有效，不存在损害公司及全体股东 利益的情形。非独立董事候选人郑强国先生、朱然先生、梅 治福先生、张冬波先生、陈强先生、盛小莉女士符合上市公 司董事的任职资格，具备《公司法》等法律法规以及《公司 根据《中华人民共和国公司法》《深圳证券交易所创业 板股票上市规则》等相 ...

中信建投证券股份有限公司关于中金辐照股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：中金辐照 | | --- | --- | | 保荐代表人姓名：伍春雷 | 联系电话：0755-23953851 | | 保荐代表人姓名：李波 | 联系电话：0755-23953869 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | (1)是否及时审阅公司信息披露文件 | 是 | | (2)未及时审阅公司信息披露文件的次数 | 0 次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | (1)是否督导公司建立健全规章制度(包括但不限 | | | 于防止关联方占用公司资源的制度、募集资金管 | 是 | | 理制度、内控制度、内部审计制度、关联交易制度) | | | (2)公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | (1)查询公司募集资金专户次数 | 次 1 | | (2)公司募集资金项目进展是否与信息披露文件一 | 是 | | 致 | | | 4 ...

提名人中金辐照股份有限公司董事会现就提名胡锡云为中金辐 照股份有限公司第四届董事会独立董事候选人发表公开声明。被提 名人已书面同意出任中金辐照股份有限公司第四届董事会独立董事 候选人。本次提名是在充分了解被提名人职业、教育背景、专业资 格、工作经历、全部兼职等情况后作出的，本提名人认为被提名人 符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明 并承诺如下事项： 一、被提名人已经通过中金辐照股份有限公司第三届董事会提名委 员会资格审查，提名人与被提名人不存在利害关系或者可能妨碍被 提名人独立履职的其他关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等 规定不得担任公司董事的情形。 √ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深 圳证券交易所自律监管规则规定的独立董事任职资格和条件。 √ 是 □ 否 四、被提名人符合公司章程规定的独立董事任职条件。 √ 是 □ 否 五、被提名人已经参加培训且培训时长符合中国证监会和深圳证券 交易所要求，并取得证券交易所认可的相关培训证明材料。尚未参 加 ...

Group 1: Business Overview - The main application areas for the company's irradiation technology services include healthcare products, food, pharmaceuticals, daily necessities, packaging materials, and polymer materials, all of which show good growth potential [1] - The company currently operates 10 large gamma irradiation devices and 5 accelerator devices (including 3 under construction), making it a leading enterprise in China's irradiation technology service industry [3] Group 2: Market and Growth Potential - The demand for healthcare products and pharmaceuticals is expected to rise due to advancements in medical science and increased public health awareness [1] - The irradiation market is anticipated to grow as the public's quality of life improves and the demand for better living standards increases [4] Group 3: Technology and Competitive Advantage - The company utilizes both cobalt-60 and electron beam irradiation technologies, each with distinct advantages, and they are not likely to fully replace each other [2] - Gamma irradiation technology is characterized by a broad sterilization spectrum, strong penetration, and environmental friendliness, making it superior to traditional sterilization methods [4] Group 4: Financial Performance - The company's gross margin has been steadily increasing due to market expansion and improved operational efficiency [5] - The supply of cobalt sources is stable, and the procurement prices have been stabilizing over the past two years [5] Group 5: Strategic Development - The company plans to optimize its investment layout and accelerate development by establishing new sites or through acquisitions [3] - The core team consists of experienced professionals in various fields, and the company has implemented incentive mechanisms to enhance employee motivation and creativity [6]

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 | --- | --- | |------------------------|--------------------------------------------------------| | | 编号：2023004 | | 投资者关系活动 | 特定对象调研 分析师会议 媒体采访 业绩说明会 | | 类别 | 新闻发布会路演活动现场参观 其他 | | 参与单位名称及人员姓名 | 东兴证券（任天辉） | | 时间 | 2023 年 5 月 12 日 上午 10:00—11:00 | | 地点 | 中金辐照会议室 | | 上市公司接待人 | 副总经理于梅女士、董事会秘书杨先刚先生、证券事务代表曹 | | 员姓名 | 婷女士 | | | 1.公司目前γ射线辐照站在钴 60 全球涨价趋势下上游供 | | | 应情况如何?EB 电子束辐照未来替换钴源辐照站趋势是否明 | | | 朗，公司产能扩建是否受 EB 加速器产能限制? | | | 答：公司与国内外主要的钴源供应商都建立了长期的合作 | | | 关系，多年来钴源供应商都 ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2023005 | 特定对象调研 | 分析师会议 媒体采访  业绩说明会 | 投资者关系活动 | | --- | --- | --- | | 新闻发布会 | 路演活动 现场参观 其他 | 类别 | | 中金辐照 2022 | 年度网上业绩说明会采用网络远程方式进行， | 参与单位名称及 | | 面向全体投资者 | | 人员姓名 | | 2023 年 5 | 月 15 日 上午 10:00—11:30 | 时间 | | 深圳证券交易所"互动易平台"（http://irm.cninfo.com.cn） | | 地点 | | "云访谈"栏目 | | | | 董事长、党委书记郑强国先生，董事、总经理张冬波先生，独 | | 上市公司接待人 | | 立董事张伟女士、总会计师张嫚草女士、副总经理于梅女士、 | 董事会秘书杨先刚先生、保荐代表人伍春雷先生 | 员姓名 | | 本次网上业绩说明会采用网络远程的方式举行，投资者登 | 陆深圳证券交易所"互动易"平台"云访谈"栏目参与本次业 | | | 绩说明会。本次业绩说 ...

中金辐照股份有限公司 证券代码：300962 证券简称：中金辐照 公告编号：2023-042 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 中金辐照股份有限公司（以下简称"公司"）《2022 年年度报 告》及《2022 年年度报告摘要》已于 2023 年 4 月 22 日在中国证 监会指定的创业板上市公司信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露。为了更好地与广大投资者进 行交流，使投资者能够进一步了解公司的生产经营情况，公司定于 2023 年 5 月 15 日（星期一）上午 10:00—11:30 在深圳证券交易 所"互动易"平台"云访谈"栏目举行 2022 年度网上业绩说明会（以 下简称"本次说明会"），现将有关事项公告如下： 一、本次说明会将采用网络远程的方式举行，投资者可登陆深圳 证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云 访谈"栏目参与本次会议。 二、出席本次业绩说明会的人员有：公司董事长、党委书记郑强 国先生，董事、总 ...

Financial Performance - The company's revenue for Q1 2023 was ¥80,334,442.58, representing a 1.90% increase compared to ¥78,834,006.63 in the same period last year[4] - Net profit attributable to shareholders was ¥29,302,851.57, up 2.88% from ¥28,482,576.99 year-on-year[4] - The net profit for Q1 2023 was CNY 30,768,208.98, an increase of 4.4% compared to CNY 29,469,515.58 in Q1 2022[16] - The total profit amounted to CNY 35,736,977.07, up from CNY 34,512,380.97, reflecting a growth of 3.5% year-over-year[16] - Operating income for the quarter was CNY 35,726,939.73, compared to CNY 34,487,040.38 in the previous year, indicating a rise of 3.6%[16] - Basic and diluted earnings per share were both CNY 0.1110, up from CNY 0.1079 in the previous year[17] Cash Flow and Liquidity - The net cash flow from operating activities was ¥38,835,242.83, reflecting a 1.81% increase from ¥38,146,128.83 in the previous year[4] - The company's cash and cash equivalents decreased from CNY 348,810,983.68 at the beginning of the year to CNY 321,763,700.59 by the end of Q1 2023, a decline of approximately 7.8%[11] - Cash and cash equivalents at the end of the period totaled CNY 348,810,983.68, an increase from CNY 336,538,005.28 at the end of Q1 2022[20] - The cash flow from operating activities was CNY 38,835,242.83, slightly up from CNY 38,146,128.83 in the same period last year[19] - The cash flow from investing activities resulted in a net outflow of CNY 7,031,611.65, an improvement from a net outflow of CNY 16,782,677.28 in Q1 2022[20] - The company’s operating cash inflow totaled CNY 84,839,350.68, compared to CNY 73,072,873.94 in the same quarter last year, reflecting a growth of 16.1%[19] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,104,020,717.93, marking a 3.23% increase from ¥1,069,442,193.97 at the end of the previous year[4] - Non-current assets increased from CNY 682,912,603.38 to CNY 701,363,189.78, indicating a growth of approximately 2.5%[12] - The company's total liabilities decreased from CNY 156,102,257.21 to CNY 152,291,942.23, reflecting a reduction of approximately 2.5%[13] - Total assets decreased from CNY 1,104,020,717.93 to CNY 1,069,442,193.97, a decline of about 3.1%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,673[8] - The largest shareholder, China National Gold Group Corporation, holds 54.20% of the shares, with 25,353,573 shares pledged[8] Other Income and Expenses - Other income rose by 131.29% year-on-year, primarily due to an increase in government subsidies received[7] - Research and development expenses for Q1 2023 were CNY 4,772,873.34, compared to CNY 4,477,839.20 in the previous year, marking an increase of approximately 6.6%[14] - The company incurred a credit impairment loss of CNY 483,658.44, compared to CNY 800,201.96 in the previous year, showing a decrease of 39.5%[16] Return on Equity - The weighted average return on equity slightly decreased to 3.25% from 3.31% in the previous year[4]

Financial Performance - The company's operating revenue for 2022 was CNY 337,129,684.48, representing a 9.08% increase from CNY 309,072,018.55 in 2021[23]. - The net profit attributable to shareholders for 2022 was CNY 107,726,331.01, a 23.65% increase compared to CNY 87,119,688.54 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 105,243,913.31, up 30.95% from CNY 80,371,540.97 in 2021[23]. - The basic earnings per share for 2022 was CNY 0.4081, reflecting a 15.94% increase from CNY 0.3520 in 2021[23]. - The total assets at the end of 2022 amounted to CNY 1,069,442,193.97, a 6.81% increase from CNY 1,001,235,522.57 at the end of 2021[23]. - The net assets attributable to shareholders at the end of 2022 were CNY 887,279,263.40, which is a 4.93% increase from CNY 845,553,406.64 in 2021[23]. - The cash flow from operating activities for 2022 was CNY 185,428,812.96, a 5.63% increase from CNY 175,550,139.58 in the previous year[23]. - The weighted average return on equity for 2022 was 12.43%, up from 11.27% in 2021[23]. - The company achieved total assets of 1,069.44 million and net profit of 110.63 million, representing a year-on-year growth of 21.83%[74]. - The company's operating revenue reached 337.13 million, an increase of 9.08% compared to the previous year[74]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares, based on a total of 264,001,897 shares[4]. - The company has implemented a dividend proposal of 3.00 yuan (tax included) per 10 shares for the 2022 annual dividend, providing good returns to shareholders[74]. - The total number of shares for the dividend distribution is based on 264,001,897 shares, with no stock repurchase involved[186]. Market and Industry Insights - The domestic nuclear technology application industry has a market value exceeding 300 billion, with an annual growth rate exceeding 20%[35]. - The irradiation technology service industry in China is concentrated in economically developed regions, with Shanghai, Jiangsu, Guangdong, and Zhejiang accounting for over 60% of the industry scale[36]. - The company primarily engages in irradiation technology services, focusing on sterilization for medical products, food, and packaging materials, which is its main source of revenue and profit[38]. - The company operates under the umbrella of China National Gold Group, which is one of the seven major business sectors[38]. - The company is actively expanding its market presence in provinces like Anhui and Hubei, and is advancing projects such as the X target technology and the Tianjin project[77]. Research and Development - The company has developed 30 new technology research projects in 2022, including studies on dose distribution in electron accelerator irradiation processing[61]. - The company launched 30 new R&D projects in 2022, including studies on electron accelerator irradiation dose distribution and response relationships of different types of dosimeters[78]. - Research and development expenses increased by 22.15% to ¥25,761,357.40 compared to the previous year[92]. - R&D investment amounted to ¥25,761,357.40 in 2022, representing 7.64% of operating revenue, up from 6.82% in 2021[95]. - The company aims to provide better technical services and improve customer satisfaction through its R&D efforts[94]. Operational Efficiency and Cost Management - The overall cost savings from comprehensive cost control in 2022 amounted to ¥2,063,000, achieving 140.6% of the annual budget target of ¥1,467,500[79]. - The company emphasizes cost control and operational efficiency, aiming to improve quality and efficiency through comprehensive budget management and digital applications[122]. - The company’s fixed costs, including depreciation of irradiation equipment, create a scale effect that enhances profitability as regional markets mature[48]. Quality Management and Compliance - The company maintains a quality management system aligned with international standards, focusing on long-term cooperation and win-win relationships with clients[51]. - The company has established a comprehensive quality management system that meets ISO standards, which has been recognized by domestic and international clients[52]. - The company has effective business licenses in multiple countries, including the Ministry of Ecology and Environment of the People's Republic of China and the FDA in the United States, ensuring compliance with international standards[52]. - The internal control system has been strengthened, covering procurement, production, sales, quality control, human resources, and finance[189]. Corporate Governance and Shareholder Engagement - The company has been recognized as a "Demonstration Enterprise of Corporate Governance" by the State-owned Assets Supervision and Administration Commission due to its effective governance practices[131]. - The company conducted two shareholder meetings during the reporting period, ensuring all resolutions were passed legally and effectively, enhancing participation from minority shareholders[132]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, and operations, ensuring a complete business system[141]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[136]. Future Outlook and Strategic Initiatives - The company aims to achieve a revenue target of 348.61 million yuan and a net profit target of 107.8 million yuan for 2023[120]. - The company plans to enhance market expansion and optimize its layout by increasing the development of new technology applications and fields[121]. - The company is focusing on expanding its market presence through nine strategic initiatives, including market expansion and technological innovation[118]. - The company anticipates significant growth opportunities in the civil nuclear technology industry, supported by favorable national policies and increasing market demand[119].